Sarepta Therapeutics Inc (SRPT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $19.89 (-3.77%), Market cap $1.79B, P/E ratio 48.37, 52-week low–high $11.93 ~ $43.01.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and EL
Financial statements, price targets, institutional (13F) holdings and related news for Sarepta Therapeutics Inc are updated in real time on BlackAll Trade.
Sarepta Therapeutics Inc trades at $19.89 (-3.77%). Real-time quotes and charts are available on BlackAll Trade.
Sarepta Therapeutics Inc has a market cap of about $1.79B. Its P/E ratio is 48.37.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therape